Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klapper

Showing results (1031-1040 of 1,153) with videos related to

Pageof 116
Sort By:
International Journal of Molecular Sciences|January 8, 2025
Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot StudyLorenz Oelschläger, Axel Künstner, Friederike Frey, et al.
Blood|August 26, 2010
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHLGerman Ott, Marita Ziepert, Wolfram Klapper, et al.
Leukemia|August 22, 2017
Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencingA Zamò, J Pischimarov, M Schlesner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimensMark E Dudley, James C Yang, Richard Sherry, et al.
Blood Advances|October 28, 2022
Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphomaJakoba J Eertink, Gerben J C Zwezerijnen, Sanne E Wiegers, et al.
Leukemia|September 19, 2019
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHLAnnette M Staiger, Michael Altenbuchinger, Marita Ziepert, et al.
Blood Advances|May 24, 2022
A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profileJulia Salmeron-Villalobos, Caoimhe Egan, Vanessa Borgmann, et al.
Leukemia|December 2, 2015
Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locusE Leich, E Hoster, M Wartenberg, et al.
Leukemia|February 18, 2015
Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphomaH Horn, M Ziepert, M Wartenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2022
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Linmiao Jiang, Jan Walewski, et al.
Pageof 116

Showing results (1031-1040 of 1,153) with videos related to

Sort By:
Pageof 116
International Journal of Molecular Sciences|January 8, 2025
Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot StudyLorenz Oelschläger, Axel Künstner, Friederike Frey, et al.
Blood|August 26, 2010
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHLGerman Ott, Marita Ziepert, Wolfram Klapper, et al.
Leukemia|August 22, 2017
Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencingA Zamò, J Pischimarov, M Schlesner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimensMark E Dudley, James C Yang, Richard Sherry, et al.
Blood Advances|October 28, 2022
Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphomaJakoba J Eertink, Gerben J C Zwezerijnen, Sanne E Wiegers, et al.
Leukemia|September 19, 2019
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHLAnnette M Staiger, Michael Altenbuchinger, Marita Ziepert, et al.
Blood Advances|May 24, 2022
A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profileJulia Salmeron-Villalobos, Caoimhe Egan, Vanessa Borgmann, et al.
Leukemia|December 2, 2015
Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locusE Leich, E Hoster, M Wartenberg, et al.
Leukemia|February 18, 2015
Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphomaH Horn, M Ziepert, M Wartenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2022
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Linmiao Jiang, Jan Walewski, et al.
Pageof 116